← Back to Search

MDM2 Inhibitor

RAIN-32 for Pancreatic Cancer

Phase 2
Waitlist Available
Research Sponsored by Rain Oncology Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first dose date to first cr, pr, or stable disease (sd) >= 16 weeks, or study completion date; up to 23.5 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing milademetan, a medication for patients with advanced or metastatic solid tumors that haven't responded to other treatments. It targets specific genetic features in cancer cells to stop them from growing.

Eligible Conditions
  • Stomach Cancer
  • Pancreatic Cancer
  • Cholangiocarcinoma
  • Ovarian Cancer
  • Adrenal Cortex Carcinoma
  • Bladder Cancer
  • Solid Tumors
  • Non-Small Cell Lung Cancer
  • Sarcoma
  • Head and Neck Cancers
  • Testicular Cancer
  • Bile Duct Cancer
  • Lung Adenocarcinoma
  • Breast Cancer
  • Melanoma
  • Gene Amplification
  • Cervical Cancer
  • Adrenocortical Cancer
  • Biliary Tract Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first dose date to first cr, pr, or stable disease (sd) >= 16 weeks, or study completion date; up to 23.5 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose date to first cr, pr, or stable disease (sd) >= 16 weeks, or study completion date; up to 23.5 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To Determine the ORR of Treatment With Milademetan in Patients With Advanced/Metastatic Solid Tumors With MDM2 Gene Amplification.
Secondary study objectives
Disease Control Rate (DCR)
Duration of Response (DOR)
Growth Modulation Index (GMI)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Milademetan (RAIN-32)Experimental Treatment1 Intervention
260 mg once dailly orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle

Find a Location

Who is running the clinical trial?

Rain Oncology IncLead Sponsor
8 Previous Clinical Trials
279 Total Patients Enrolled
Rain Therapeutics Inc.Lead Sponsor
4 Previous Clinical Trials
242 Total Patients Enrolled

Media Library

Milademetan (MDM2 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05012397 — Phase 2
Pancreatic Cancer Research Study Groups: Milademetan (RAIN-32)
Pancreatic Cancer Clinical Trial 2023: Milademetan Highlights & Side Effects. Trial Name: NCT05012397 — Phase 2
Milademetan (MDM2 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05012397 — Phase 2
Pancreatic Cancer Patient Testimony for trial: Trial Name: NCT05012397 — Phase 2
~10 spots leftby Dec 2025